ChartRow logo
EXEL
$72.77+0.64%
as of close, Nov 4, 2026
☾ AH $72.77 +0.64%
Share this page

EXEL — Exelixis Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
What would $1,000 invested in EXEL be worth today? →
EXEL returns: By year · By month · By week · Trailing

Key stats#

Price data

Price
$72.77
YTD price return
+66.03%
YTD total return
+66.03%
Market cap
17.8B
Enterprise value
17.1B
Shares outstanding
244M
52W low
$37.58
52W high
$73.44
From 52W high
-0.91%
From 52W low
+93.64%
52W range
98%$37.58–$73.44
Beta
0.41

Volume

Rel volume
2.18×
30D volume
2.6M
30D $ vol
163.8M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
−$527K
Insider net 1Y
−$31.8M

Form 4 transactions by trade date, as filed; latest on file 2026-08-10.

Fundamentals

Sales (ttm)
2.5B
Sales/share
$10.23
EPS (ttm)
$3.34
FCF (ttm)
1.2B
FCF/share
$4.76
Book value/share
$7.52
Net margin
35.45%
ROE
48.27%
ROA
35.22%
Current ratio
3.21

Growth (CAGR, ttm) · 10Y

Sales
+9.15%+12.02%+14.76%+35.02%
Net income
+30.69%+112.16%+40.03%n/a
FCF
+49.11%+47.66%+33.36%+29.28%
Shares
-9.02%-7.74%-5.06%-1.59%

Per-share growth (CAGR, ttm) · 10Y

EPS
+41.28%+126.98%+45.63%n/a
Sales/share
+19.97%+21.42%+20.88%+37.21%
FCF/share
+63.89%+60.05%+40.47%+31.37%
Book value/share
-6.77%-0.15%+2.39%+52.29%
Price
+92.09%+51.25%+30.91%+21.71%
Total return
+92.09%+51.25%+30.91%+21.71%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
21.8×
P/OI (ttm)
17.7×
Fwd P/E
16.7×
P/S (ttm)
7.1×
P/B (mrq)
9.7×
P/FCF (ttm)
15.3×
EV/EBITDA (fy)
16.5×
EV/Sales (ttm)
6.8×
FCF yield (ttm)
6.54%
Buyback yield (realized, 1y)
9.02%
Shareholder yield (realized, 1y)
9.02%
Buyback yield (cash, ttm)
7.10%
Shareholder yield (cash, ttm)
7.10%

Vs own 10Y history

P/E
42nd
P/OI
42nd
P/S
69th
P/B
86th
P/FCF
30th

Bar = where today’s multiple sits in EXEL’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-04#

1D
+0.64%
5D
+9.79%
1M
+24.63%
3M
+29.95%
YTD
+66.03%
1Y
+92.01%
5Y
+284.42%
1D
+0.64%
5D
+9.79%
1M
+24.63%
3M
+29.95%
YTD
+66.03%
1Y
+92.01%
5Y
+284.42%

Fundamentals#

Revenue

5Y CAGR +18.6%10Y CAGR +51.2%YoY +10.2%
$2.5B TTM$658.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +51.3%10Y n/mYoY +13.5%
$1B TTM$268.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +51.4%10Y n/mYoY +23.2%
$3.34 TTM$0.85 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +37.4%10Y n/mYoY −3.9%
$1.2B TTM$277.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $1.2B, capex −$12M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $280M, capex −$2.5M

Shares (diluted)

5Y −11.4%10Y +34.7%YoY −8.2%
264.8M TTM255.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +47.6%10Y n/mYoY +12.7%
$885.1M TTM$218.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full EXEL financials →

About Exelixis#

Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in clinical practice. Exelixis also advances a broader pipeline of small-molecule and biotherapeutic candidates aimed at expanding treatment options in solid tumors and other oncology settings. In addition to internal drug development, the company works through collaborations to support research, development, and commercialization activities. Based in Alameda, California, Exelixis plays a significant role in the cancer treatment market by combining approved products with an active development pipeline focused on targeted oncology medicines.

Alameda, CA·1,077 employees·Biotechnology·exelixis.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding EXEL#

25 of the 193 ETFs ChartRow carries live hold EXEL. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF1.0%
XBISPDR S&P Biotech ETF1.0%
IJHiShares Core S&P Mid-Cap ETF0.4%
MDYSPDR S&P MidCap 400 ETF Trust0.4%
VBKVanguard Small-Cap Growth ETF0.4%
VHTVanguard Health Care ETF0.2%
VXFVanguard Extended Market ETF0.2%
VBVanguard Small-Cap ETF0.2%
TickerName1M1D
LLYEli Lilly and Company+24.07%+0.61%
JNJJohnson & Johnson+7.92%+3.81%
ABBVAbbVie Inc.+12.18%+3.09%
MRKMerck & Co. Inc.+4.20%+3.93%
UNHUnitedHealth Group Incorporated Common Stock (DE)+10.08%+1.22%
NVSNovartis AG+17.01%+3.59%
TMOThermo Fisher Scientific Inc.+7.84%+1.12%
AMGNAmgen Inc.+18.69%+3.71%